Novartis & American Company Partner on Autoimmune Disease Development
- Novartis is expanding its collaboration with Monte Rosa Therapeutics to develop new treatments for autoimmune diseases, according to a Reuters report from September 2025.
- Autoimmune diseases occur when the body's immune system mistakenly attacks healthy tissues and organs.
- Under the agreement,Novartis gains exclusive rights to an undisclosed drug in development and options to license two additional early-stage programs from Monte Rosa.
Okay, I will rewrite the provided text according to your specifications. Here’s the revised version:
Novartis Partners with Monte rosa Therapeutics to Develop Autoimmune Disease Drugs
Table of Contents
Novartis is expanding its collaboration with Monte Rosa Therapeutics to develop new treatments for autoimmune diseases, according to a Reuters report from September 2025.
Tackling Autoimmune Diseases with AI-Driven Drug discovery
Autoimmune diseases occur when the body’s immune system mistakenly attacks healthy tissues and organs. These conditions are frequently enough tough to treat and can significantly impair a patient’s quality of life.
Under the agreement,Novartis gains exclusive rights to an undisclosed drug in development and options to license two additional early-stage programs from Monte Rosa. Monte Rosa Therapeutics will leverage its artificial intelligence (AI) platform to discover and develop “degraders,” small molecules designed to break down disease-causing proteins. Novartis will then handle clinical development and marketing.
Expanding Existing Collaboration
This agreement marks the second partnership between Novartis and monte Rosa. The companies previously collaborated on MRT-6160, a drug currently in early clinical trials for autoimmune and inflammatory conditions.
Strategic Deals for Novartis
The monte Rosa agreement is the second major transaction for Novartis this month. Earlier in September 2025, Novartis announced a partnership with Argo Biopharmaceutical, a Chinese company, for experimental drugs, potentially worth up to $5.2 billion.
In the prior week, Novartis announced its intent to acquire Tourmaline Bio, an American biopharmaceutical company that developed a promising drug for atherosclerotic cardiovascular disease, for $1.4 billion.